MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD

MAPS has announced that a blinded administrative interim analysis has confirmed no changes to the planned sample size are necessary to provide sufficient statistical power to detect the efficacy of MDMA-assisted therapy for PTSD in the second of two Phase III trials. Per their agreement with the FDA, the Phase III trial was designed to enrol at least 100 participants in order to confirm the efficacy and further investigate the safety of the treatment.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Topic PTSD
Compound MDMA
Visit article
Category Press Release
Published in Cision

Companies Featured

MAPS stands for Multidisciplinary Association for Psychedelic Studies, it's the front runner in making psychedelics a legal way to use (and improve) in therapy.

Inline Feedbacks
View all comments